SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Implementing LA-ARVs in Europe: Which Patient? Which Formulation?View Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022HIV Transmission Clusters in Europe: A Perspective View of Late Presenters and Non-Late PresentersView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Transmitted Drug Resistance to Integrase Based First-Line Treatment in Europe, 2018-2021View Slideset
AMAnne-Geneviève MarcelinMDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022New Antiretroviral Compounds: What Are the Resistance Concerns?View Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022New Antiretroviral Compounds: What Are the Resistance Concerns?View Slideset
LVLinos VandekerckhoveMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022The Top 10 Important Observations Last YearView Slideset
EGEnrico GirardiMDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Country Experiences: Southern Europe / ItalyView Slideset
JAJan AlbertMD, PhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Country Experiences: Northern Europe / SwedenView Slideset
DJDavid JilichMD, Ph.DSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Country Experiences: Eastern Europe / Czech RepublicView Slideset
SCSimon CauchemezPhDSlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Country Experiences: Western Europe / FranceView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Levels and Durability of Humoral and T-Specific Responses After the Booster Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care FacilityView Slideset
SlidesetHIVViral Hepatitis and Liver DiseaseEuropean Meeting on HIV & Hepatitis 2022Impact of Sars-Cov-2 Omicron and Delta Sub-Lineage AY.4.2 Variant on Neutralization by Sera of Patients Treated With Different Licensed Monoclonal AntibodiesView Slideset
